Rankings
▼
Calendar
MIRM Q4 2025 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
MIRM
Mirum Pharmaceuticals, Inc.
$5B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$149M
+49.8% YoY
Gross Profit
$121M
81.0% margin
Operating Income
-$5M
-3.1% margin
Net Income
-$6M
-3.8% margin
EPS (Diluted)
$-0.12
QoQ Revenue Growth
+12.0%
Cash Flow
Operating Cash Flow
$6M
Free Cash Flow
$5M
Stock-Based Comp.
$19M
Balance Sheet
Total Assets
$843M
Total Liabilities
$528M
Stockholders' Equity
$315M
Cash & Equivalents
$297M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$149M
$99M
+49.8%
Gross Profit
$121M
$77M
+57.4%
Operating Income
-$5M
-$24M
+81.1%
Net Income
-$6M
-$24M
+75.9%
Revenue Segments
Product
$149M
100%
Geographic Segments
UNITED STATES
$115M
100%
← FY 2025
All Quarters